Company News: AstraZeneca

Share this article:
AstraZeneca announced plans to cut 8,000 jobs -- around 12% of its global workforce -- by 2014 as part of a cost-cutting exercise. The firm, which has already eliminated 12,600 jobs in recent years, will lose US market exclusivity on Arimidex and Pulmicort Respules this year and has projected a revenue decline in the mid-single digits for the year. The company will also restructure its R&D function to focus on fewer disease area targets and close some R&D sites.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.